Pipeline



Our lead program: cytoTIL15

Engineered to make TILs more effective for more patients




✔ Engineered with membrane-bound IL15

✔ Eliminates toxic IL2 regimen, increasing patient accessibility to TIL therapy

✔ Drives improved persistence

✔ IL15 expression controlled by acetazolamide (ACZ), via cytoDRiVE® technology

Pipeline

 
 
Discovery
Preclinical
IND Enabling
cytoTIL
 
 
 
 
cytoTIL15 | Melanoma
 
 
IND Enabling
 
 
 
 
 
cytoTIL15 | HNSCC
 
 
Preclinical
cytoTIL
 
 
 
 
cytoTIL15 | Cervical, NSCLC, Additional Solid Tumors
 
 
Discovery
 
 
 
 
 
cytoTILx-1 | Undisclosed
 
 
Discovery
 
 
 
 
 
cytoTILx-2 | Undisclosed
 
 
Discovery
Partnered Programs
 
 
 
 
CD40L | Undisclosed   Bristol-Myers Squibb™
 
 
IND Enabling
Partnered Programs
 
 
 
 
IL12 | Undisclosed   Bristol-Myers Squibb™
 
 
Preclinical
 
 
 
 
 
Gene Editing | Undisclosed   Vertex
 
 
Discovery